Cencora said its revenue for fiscal 2024 Q3 (ended June 30) rose 10.9% year over year to $74.2 billion, with GAAP diluted EPS of $2.42 (versus $2.35 a year earlier) and adjusted diluted EPS of $3.34 (versus $2.92 a year earlier).

1. 01

   Cencora said its revenue for fiscal 2024 Q3 (ended June 30) rose 10.9% year over year to $74.2 billion, with GAAP diluted EPS of $2.42 (versus $2.35 a year earlier) and adjusted diluted EPS of $3.34 (versus $2.92 a year earlier).

2. 02

   The company said revenue in U.S. Healthcare Solutions rose 12.2% in Q3, while gross profit margin fell 13 basis points from a year earlier to 3.25%, which it attributed to increased sales of lower-margin GLP-1-class products labeled for diabetes and/or weight loss.

3. 03

   The company raised its fiscal 2024 adjusted diluted EPS guidance to $13.55 to $13.65 from the prior range of $13.35 to $13.55, and it now expects adjusted free cash flow of $2.5 billion to $3.0 billion, up from the previous expectation of approximately $2.5 billion.

4. 04

   The company said GAAP operating expenses for Q3 rose 9.0% year over year to $1.7 billion, citing litigation and opioid-related expenses in the current period, compared with a credit in the prior-year quarter.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.